Coldstream Capital Management Inc C4 Therapeutics, Inc. Transaction History
Coldstream Capital Management Inc
- $4.64 Billion
- Q1 2025
A detailed history of Coldstream Capital Management Inc transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Coldstream Capital Management Inc holds 52 shares of CCCC stock, worth $84. This represents 0.0% of its overall portfolio holdings.
Number of Shares
52Holding current value
$84% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CCCC
# of Institutions
129Shares Held
64.2MCall Options Held
507KPut Options Held
103K-
Soleus Capital Management, L.P. Greenwich, CT6.98MShares$11.3 Million1.75% of portfolio
-
Lynx1 Capital Management LP San Juan, PR6.85MShares$11.1 Million9.58% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT6.07MShares$9.84 Million0.11% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.88MShares$7.9 Million0.28% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$7.37 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $79.2M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...